Article

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

the Laboratory of Microbiology, Wageningen University, Wageningen (S.F., E.G.Z., W.M.V.)
New England Journal of Medicine (Impact Factor: 54.42). 01/2013; 368(5). DOI: 10.1056/NEJMoa1205037
Source: PubMed

ABSTRACT Background Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in patients with recurrent C. difficile infection. Methods We randomly assigned patients to receive one of three therapies: an initial vancomycin regimen (500 mg orally four times per day for 4 days), followed by bowel lavage and subsequent infusion of a solution of donor feces through a nasoduodenal tube; a standard vancomycin regimen (500 mg orally four times per day for 14 days); or a standard vancomycin regimen with bowel lavage. The primary end point was the resolution of diarrhea associated with C. difficile infection without relapse after 10 weeks. Results The study was stopped after an interim analysis. Of 16 patients in the infusion group, 13 (81%) had resolution of C. difficile-associated diarrhea after the first infusion. The 3 remaining patients received a second infusion with feces from a different donor, with resolution in 2 patients. Resolution of C. difficile infection occurred in 4 of 13 patients (31%) receiving vancomycin alone and in 3 of 13 patients (23%) receiving vancomycin with bowel lavage (P<0.001 for both comparisons with the infusion group). No significant differences in adverse events among the three study groups were observed except for mild diarrhea and abdominal cramping in the infusion group on the infusion day. After donor-feces infusion, patients showed increased fecal bacterial diversity, similar to that in healthy donors, with an increase in Bacteroidetes species and clostridium clusters IV and XIVa and a decrease in Proteobacteria species. Conclusions The infusion of donor feces was significantly more effective for the treatment of recurrent C. difficile infection than the use of vancomycin. (Funded by the Netherlands Organization for Health Research and Development and the Netherlands Organization for Scientific Research; Netherlands Trial Register number, NTR1177 .).

Download full-text

Full-text

Available from: Susana Fuentes, Jan 24, 2014
0 Followers
 · 
301 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Inflammatory bowel diseases (IBDs) are chronic debilitating disorders of unknown etiology, consisting of two main conditions, ulcerative colitis and Crohn's disease. Major advances have recently taken place in human genetic studies of IBD and over 160 risk loci for these two diseases have been uncovered. These genetic data highlight a key role for genes that code for immunological and epithelial barrier functions. Environmental factors also make substantial contributions to the pathogenesis of IBD and account for the growing incidence of the diseases around the world. Intestinal microbiota creates resistance to infection, provides nutrients, and educates the immune system and in many ways has a significant impact on human health. Aberrant microbiota composition and decreased diversity (dysbiotic microbiota) are key etiopathological events in IBD. Dysbiotic microbiota can lead to loss of normal, regulatory immune effects in the gut mucosa. This may play a central role in the development and perpetuation of chronic inflammation. Further, the expression of specific innate immune receptors that recognize microbes is altered in the IBD epithelium. Therefore, the combination of host side epithelial barrier functions and the presence of dysbiotic microbiota in the gut together promote inflammation. New therapeutic options targeting microbiota are currently considered for IBD and they may, in the future, provide means to reverse the pathogenic host-microbiota relationship into a symbiotic one. In this review, the focus is on the intestinal microbiota and host-microbe interactions in IBD.
    Scandinavian Journal of Gastroenterology 01/2015; 50(1):34-42. DOI:10.3109/00365521.2014.966320 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: How to regulate faecal transplants ? Responding to Smith et al. (Nature, 2014), this paper argues that for medical use, faecal microbiota transplantation (FMT) should be considered a sui generis biological drug, rather than a tissue. Smith and colleagues’ thesis is based on possible undesirable economic consequences of this designation — not on its scientific and conceptual basis. The faecal trans- plant (including gut microbiota, metabolites, mucus, human cells, viruses, fungi, etc.) is not a tissue; it is of topographic — not cellular — human origin. We consider the donor a bioreactor, producing the faecal substrate of therapeutic interest. The debate is of singular importance as the FDA considers FMT a drug and released a new guidance for public consultation in February 2014, whereas to date the European Medicines Agency has not promulgated its position. The UK’s National Institute for Heath and Care Excellence does not consider FMT to involve the transplantation of body tissue, and in March 2014 the French regulatory agency ANSM expressly declared it to be a drug. As FM is a complex and highly variable admixture, its components cannot be completely characterized, and to date, compositional quality cannot be assessed. We consider FMT to be a sui generis biologic drug, albeit one prepared with unconventional raw material under microbiologic control. The possibility of associating identified bacterial species with particular diseases and cultivating selected bacteria of therapeutic interest would certainly define a second generation of microbiome therapeutics, but is still speculative.
    Annales Pharmaceutiques Françaises 04/2014; Ann Pharm Fr(354). DOI:10.1016/j.pharma.2014.04.008
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The human intestinal microbiota is our main bacterial reservoir with 1013–1014 cells. It is divided into a permanent (or resident) microbiota, which provides several benefits to its host, and a variable microbiota, made of exogenous bacteria that cannot sustainably settle because of the ‘barrier effect’ exerted by anaerobic bacteria. The intestinal microbiota is besides a major reservoir for antibiotic-resistant bacteria, which can be enriched by acquired multidrug-resistant bacteria such as enterobacteria that produce extended-spectrum beta-lactamases (ESBL) or carbapenemases. Antibiotics play a key role in this phenomenon in decreasing the species diversity within the intestinal microbiota while promoting the growth of resistant bacteria. In this review, we will see how the intestinal microbiota stands at the very heart of bacterial multidrug-resistance. We will tackle the different phases of the colonization by resistant bacteria and their underlying determinants, particularly the role played by antibiotics and the influence of the intestinal densities of multidrug-resistant bacteria on infections and patient-to-patient transmission. Eventually, we will review the current perspectives and those to come to combat the intestinal colonization by multidrug-resistant bacteria.
    12/2013; DOI:10.1016/j.antinf.2013.08.002